25/11/22

Building Africa’s capacity for vaccine production

President Cyril Ramaphosa and Deputy President David Mabuza lead an oversight visit to Aspen Pharmacare sterile manufacturing facility at Gqeberha in the Eastern Province.
South Africa's president visits Aspen Pharmacare, the manufacturing facility focused on progress in vaccine production at Gqeberha, South Africa.  Copyright: BABA JIYANE,GovernmentZA/ CC BY-ND 2.0

Send to a friend

The details you provide on this page will not be used to send unsolicited email, and will not be sold to a 3rd party. See privacy policy.

Listen on Apple PodcastsListen on SpotifyListen on Google PodcastsListen on StitcherListen on OvercastListen on Amazon MusicListen on CastboxListen on Podcast AddictListen on Pocket CastsListen on iHeartRadioListen on PandoraRSS Feed


Africa produces only one per cent of its routine vaccines. This leaves the region dependent on imports for its vaccine needs, and makes it vulnerable to a vaccine crisis during health emergencies.

In this episode of Africa Science Focus, Ebere Okereke, senior technical advisor at the Tony Blair Institute for Global Change and honorary senior public health advisor for the Africa Centres for Disease Control and Prevention, says research in science, and funding for therapeutics and vaccine manufacturing in the continent, must increase. Professor Claude Muvunyi, director general for the Rwanda Biomedical Centre, tells us that boosting Africa’s capacity to manufacture vaccines will be a front burner discussion during the 2nd International Conference on Public Health in Africa, scheduled to take place in Rwanda on the second week of December.

This piece was produced by SciDev.Net’s Sub-Saharan Africa English desk.